{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T21:13:48Z","timestamp":1790284428608,"version":"4.1.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T00:00:00Z","timestamp":1688515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T00:00:00Z","timestamp":1688515200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010447","name":"DZHK","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100010447","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100002839","name":"Charit\u00e9 - Universit\u00e4tsmedizin Berlin","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002839","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>COVID-19 is associated with a prothrombotic state. Current guidelines recommend prophylactic anticoagulation upon hospitalization.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>COVID-PREVENT, an open-label, multicenter, randomized, clinical trial enrolled patients (\u2265\u200918\u00a0years) with moderate to severe COVID-19 and age-adjusted <jats:sc>d<\/jats:sc>-dimers\u2009&gt;\u20091.5 upper limit of normal (ULN). The participants were randomly assigned (1:1) to receive either therapeutic anticoagulation with rivaroxaban 20\u00a0mg once daily or thromboprophylaxis with a heparin (SOC) for at least 7\u00a0days followed by prophylactic anticoagulation with rivaroxaban 10\u00a0mg once daily for 28\u00a0days or no thromboprophylaxis. The primary efficacy outcome was the <jats:sc>d<\/jats:sc>-dimer level and the co-primary efficacy outcome the 7-category ordinal COVID-19 scale by WHO at 7\u00a0days post randomization. The secondary outcome was time to the composite event of either venous or arterial thromboembolism, new myocardial infarction, non-hemorrhagic stroke, all-cause death or progression to intubation and invasive ventilation up to 35\u00a0days post randomization.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The primary efficacy outcome <jats:sc>d<\/jats:sc>-dimer at 7\u00a0days was not different between patients assigned to therapeutic (n\u2009=\u200955) or prophylactic anticoagulation (n\u2009=\u200956) (1.21\u00a0mg\/L [0.79, 1.86] vs 1.27\u00a0mg\/L [0.79, 2.04], p\u2009=\u20090.78). In the whole study population <jats:sc>d<\/jats:sc>-dimer was significantly lower at 7\u00a0days compared to baseline (1.05\u00a0mg\/L [0.75, 1.48] vs 1.57\u00a0mg\/L [1.13, 2.19], p\u2009&lt;\u20090.0001). Therapy with rivaroxaban compared to SOC was not associated an improvement on the WHO 7-category ordinal scale at 7\u00a0days (p\u2009=\u20090.085). Rivaroxaban improved the clinical outcome measured by the score in patients with a higher baseline <jats:sc>d<\/jats:sc>-dimer \u2009&gt;\u20092.0 ULN (exploratory analysis; 0.632 [0.516, 0.748], p\u2009=\u20090.026). The secondary endpoint occurred in 6 patients (10.9%) in the rivaroxaban group and in 12 (21.4%) in the SOC group (time-to-first occurrence of the components of the secondary outcome: HR 0.5; 95% CI 0.15\u20131.67; p\u2009=\u20090.264). There was no difference in fatal or non-fatal major or clinically relevant non-major bleeding between the groups.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Therapeutic anticoagulation with rivaroxaban compared to prophylactic anticoagulation with a heparin did not improve surrogates of clinical outcome in patients with moderate to severe COVID-19. Whether initial rivaroxaban at therapeutic doses might be superior to thromboprophylaxis in patients with COVID-19 and a high risk as defined by <jats:sc>d<\/jats:sc>-dimer \u2009&gt;\u20092 ULN needs confirmation in further studies.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Graphical abstract<\/jats:title>\n                \n              <\/jats:sec>","DOI":"10.1007\/s00392-023-02240-1","type":"journal-article","created":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T17:01:57Z","timestamp":1688576517000},"page":"1620-1638","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Initial therapeutic anticoagulation with rivaroxaban compared to prophylactic therapy with heparins in moderate to severe COVID-19: results of the COVID-PREVENT randomized controlled trial"],"prefix":"10.1007","volume":"112","author":[{"given":"Ursula","family":"Rauch-Kr\u00f6hnert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Puccini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marius","family":"Placzek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Beyer-Westendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Jakobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Friebel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selina","family":"Hein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirko","family":"Seidel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burkert","family":"Pieske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Massberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Witzenrath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Zeiher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Friede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan D.","family":"Anker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf","family":"Landmesser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,5]]},"reference":[{"key":"2240_CR1","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1097\/CCM.0000000000004458","volume":"48","author":"T Iba","year":"2020","unstructured":"Iba T, Levy JH, Levi M, Connors JM, Thachil J (2020) Coagulopathy of coronavirus disease 2019. Crit Care Med 48:1358\u20131364. https:\/\/doi.org\/10.1097\/CCM.0000000000004458","journal-title":"Crit Care Med"},{"key":"2240_CR2","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1056\/NEJMoa2015432","volume":"383","author":"M Ackermann","year":"2020","unstructured":"Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F, Vanstapel A, Werlein C, Stark H, Tzankov A et al (2020) Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N Engl J Med 383:120\u2013128. https:\/\/doi.org\/10.1056\/NEJMoa2015432","journal-title":"N Engl J Med"},{"key":"2240_CR3","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","volume":"395","author":"P Mehta","year":"2020","unstructured":"Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, Hlh Across Speciality Collaboration, U.K. (2020) COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 395:1033\u20131034. https:\/\/doi.org\/10.1016\/S0140-6736(20)30628-0","journal-title":"Lancet"},{"key":"2240_CR4","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.ajem.2020.09.018","volume":"39","author":"B Gungor","year":"2021","unstructured":"Gungor B, Atici A, Baycan OF, Alici G, Ozturk F, Tugrul S, Asoglu R, Cevik E, Sahin I, Barman HA (2021) Elevated d-dimer levels on admission are associated with severity and increased risk of mortality in COVID-19: a systematic review and meta-analysis. Am J Emerg Med 39:173\u2013179. https:\/\/doi.org\/10.1016\/j.ajem.2020.09.018","journal-title":"Am J Emerg Med"},{"key":"2240_CR5","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/j.chest.2020.11.005","volume":"159","author":"D Jimenez","year":"2021","unstructured":"Jimenez D, Garcia-Sanchez A, Rali P, Muriel A, Bikdeli B, Ruiz-Artacho P, Le Mao R, Rodriguez C, Hunt BJ, Monreal M (2021) Incidence of VTE and bleeding among hospitalized patients with coronavirus disease 2019: a systematic review and meta-analysis. Chest 159:1182\u20131196. https:\/\/doi.org\/10.1016\/j.chest.2020.11.005","journal-title":"Chest"},{"key":"2240_CR6","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1182\/blood.2020008086","volume":"136","author":"LN Roberts","year":"2020","unstructured":"Roberts LN, Whyte MB, Georgiou L, Giron G, Czuprynska J, Rea C, Vadher B, Patel RK, Gee E, Arya R (2020) Postdischarge venous thromboembolism following hospital admission with COVID-19. Blood 136:1347\u20131350. https:\/\/doi.org\/10.1182\/blood.2020008086","journal-title":"Blood"},{"key":"2240_CR7","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1182\/blood.2020006520","volume":"136","author":"H Al-Samkari","year":"2020","unstructured":"Al-Samkari H, Karp Leaf RS, Dzik WH, Carlson JCT, Fogerty AE, Waheed A, Goodarzi K, Bendapudi PK, Bornikova L, Gupta S et al (2020) COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection. Blood 136:489\u2013500. https:\/\/doi.org\/10.1182\/blood.2020006520","journal-title":"Blood"},{"key":"2240_CR8","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1055\/s-0037-1603929","volume":"1","author":"CM Gibson","year":"2017","unstructured":"Gibson CM, Spyropoulos AC, Cohen AT, Hull RD, Goldhaber SZ, Yusen RD, Hernandez AF, Korjian S, Daaboul Y, Gold A et al (2017) The IMPROVEDD VTE risk score: incorporation of d-dimer into the IMPROVE score to improve venous thromboembolism risk stratification. TH Open 1:e56\u2013e65. https:\/\/doi.org\/10.1055\/s-0037-1603929","journal-title":"TH Open"},{"key":"2240_CR9","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1378\/chest.10-1944","volume":"140","author":"AC Spyropoulos","year":"2011","unstructured":"Spyropoulos AC, Anderson FA Jr, FitzGerald G, Decousus H, Pini M, Chong BH, Zotz RB, Bergmann JF, Tapson V, Froehlich JB et al (2011) Predictive and associative models to identify hospitalized medical patients at risk for VTE. Chest 140:706\u2013714. https:\/\/doi.org\/10.1378\/chest.10-1944","journal-title":"Chest"},{"key":"2240_CR10","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1056\/NEJMoa1805090","volume":"379","author":"AC Spyropoulos","year":"2018","unstructured":"Spyropoulos AC, Ageno W, Albers GW, Elliott CG, Halperin JL, Hiatt WR, Maynard GA, Steg PG, Weitz JI, Suh E et al (2018) Rivaroxaban for thromboprophylaxis after hospitalization for medical illness. N Engl J Med 379:1118\u20131127. https:\/\/doi.org\/10.1056\/NEJMoa1805090","journal-title":"N Engl J Med"},{"key":"2240_CR11","doi-asserted-by":"publisher","first-page":"e192","DOI":"10.1111\/bjh.16968","volume":"190","author":"H Sivaloganathan","year":"2020","unstructured":"Sivaloganathan H, Ladikou EE, Chevassut T (2020) COVID-19 mortality in patients on anticoagulants and antiplatelet agents. Br J Haematol 190:e192\u2013e195. https:\/\/doi.org\/10.1111\/bjh.16968","journal-title":"Br J Haematol"},{"key":"2240_CR12","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1055\/s-0040-1720978","volume":"120","author":"HH Billett","year":"2020","unstructured":"Billett HH, Reyes-Gil M, Szymanski J, Ikemura K, Stahl LR, Lo Y, Rahman S, Gonzalez-Lugo JD, Kushnir M, Barouqa M et al (2020) Anticoagulation in COVID-19: effect of enoxaparin, heparin, and apixaban on mortality. Thromb Haemost 120:1691\u20131699. https:\/\/doi.org\/10.1055\/s-0040-1720978","journal-title":"Thromb Haemost"},{"key":"2240_CR13","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1093\/eurheartj\/ehab866","volume":"43","author":"Task Force for the management of, C.-o.t.E.S.o.C","year":"2022","unstructured":"Task Force for the management of, C.-o.t.E.S.o.C (2022) Corrigendum to: European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1-epidemiology, pathophysiology, and diagnosis; and ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2-care pathways, treatment, and follow-up. Eur Heart J 43:1776. https:\/\/doi.org\/10.1093\/eurheartj\/ehab866","journal-title":"Eur Heart J"},{"key":"2240_CR14","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1093\/eurheartj\/ehab697","volume":"43","author":"Task Force for the management of, C.-o.t.E.S.o.C","year":"2022","unstructured":"Task Force for the management of, C.-o.t.E.S.o.C (2022) ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2-care pathways, treatment, and follow-up. Eur Heart J 43:1059\u20131103. https:\/\/doi.org\/10.1093\/eurheartj\/ehab697","journal-title":"Eur Heart J"},{"key":"2240_CR15","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1056\/NEJMoa2105911","volume":"385","author":"PR Lawler","year":"2021","unstructured":"Investigators, A.; Investigators, A.C.-a.; Investigators, Lawler PR, Goligher EC, Berger JS, Neal MD, McVerry BJ, Nicolau JC, Gong MN et al (2021) Therapeutic anticoagulation with heparin in noncritically ill patients with Covid-19. N Engl J Med 385:790\u2013802. https:\/\/doi.org\/10.1056\/NEJMoa2105911","journal-title":"N Engl J Med"},{"key":"2240_CR16","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1056\/NEJMoa2103417","volume":"385","author":"EC Goligher","year":"2021","unstructured":"Investigators, R.-C.; Investigators, A.C.-a.; Investigators, A., Goligher EC, Bradbury CA, McVerry BJ, Lawler PR, Berger JS, Gong MN, Carrier M et al (2021) Therapeutic anticoagulation with heparin in critically ill patients with Covid-19. N Engl J Med 385:777\u2013789. https:\/\/doi.org\/10.1056\/NEJMoa2103417","journal-title":"N Engl J Med"},{"key":"2240_CR17","doi-asserted-by":"publisher","first-page":"3140","DOI":"10.1016\/j.jacc.2020.04.071","volume":"75","author":"AC Spyropoulos","year":"2020","unstructured":"Spyropoulos AC, Ageno W, Albers GW, Elliott CG, Halperin JL, Hiatt WR, Maynard GA, Steg PG, Weitz JI, Lu W et al (2020) Post-discharge prophylaxis with rivaroxaban reduces fatal and major thromboembolic events in medically ill patients. J Am Coll Cardiol 75:3140\u20133147. https:\/\/doi.org\/10.1016\/j.jacc.2020.04.071","journal-title":"J Am Coll Cardiol"},{"key":"2240_CR18","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","volume":"382","author":"B Cao","year":"2020","unstructured":"Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, Ruan L, Song B, Cai Y, Wei M et al (2020) A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med 382:1787\u20131799. https:\/\/doi.org\/10.1056\/NEJMoa2001282","journal-title":"N Engl J Med"},{"key":"2240_CR19","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1093\/infdis\/jiz656","volume":"221","author":"Y Wang","year":"2020","unstructured":"Wang Y, Fan G, Salam A, Horby P, Hayden FG, Chen C, Pan J, Zheng J, Lu B, Guo L et al (2020) Comparative effectiveness of combined favipiravir and oseltamivir therapy versus oseltamivir monotherapy in critically ill patients with influenza virus infection. J Infect Dis 221:1688\u20131698. https:\/\/doi.org\/10.1093\/infdis\/jiz656","journal-title":"J Infect Dis"},{"key":"2240_CR20","doi-asserted-by":"publisher","unstructured":"Kaatz, S.; Ahmad, D.; Spyropoulos, A.C.; Schulman, S. Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J Thromb Haemost 2015, 13, 2119\u20132126, doi:https:\/\/doi.org\/10.1111\/jth.13140.","DOI":"10.1111\/jth.13140"},{"key":"2240_CR21","doi-asserted-by":"publisher","unstructured":"Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 7). Chin Med J (Engl) 2020, 133, 1087\u20131095, doi:https:\/\/doi.org\/10.1097\/cm9.0000000000000819.","DOI":"10.1097\/cm9.0000000000000819"},{"key":"2240_CR22","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1111\/ijlh.12864","volume":"40","author":"L Zhang","year":"2018","unstructured":"Zhang L, Long Y, Xiao H, Yang J, Toulon P, Zhang Z (2018) Use of D-dimer in oral anticoagulation therapy. Int J Lab Hematol 40:503\u2013507. https:\/\/doi.org\/10.1111\/ijlh.12864","journal-title":"Int J Lab Hematol"},{"key":"2240_CR23","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1002\/jmv.26232","volume":"93","author":"B Hu","year":"2021","unstructured":"Hu B, Huang S, Yin L (2021) The cytokine storm and COVID-19. J Med Virol 93:250\u2013256. https:\/\/doi.org\/10.1002\/jmv.26232","journal-title":"J Med Virol"},{"key":"2240_CR24","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","volume":"383","author":"JH Beigel","year":"2020","unstructured":"Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E, Chu HY, Luetkemeyer A, Kline S et al (2020) Remdesivir for the Treatment of Covid-19 - Final Report. N Engl J Med 383:1813\u20131826. https:\/\/doi.org\/10.1056\/NEJMoa2007764","journal-title":"N Engl J Med"},{"key":"2240_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2023.02.041","author":"GW Stone","year":"2023","unstructured":"Stone GW, Farkouh ME, Lala A, Tinuoye E, Dressler O, Moreno PR, Palacios IF, Goodman SG, Esper RB, Abizaid A et al (2023) Anticoagulation Strategies in Non-Critically Ill Patients Hospitalized with COVID-19: A Randomized Clinical Trial. J Am Coll Cardiol. https:\/\/doi.org\/10.1016\/j.jacc.2023.02.041","journal-title":"J Am Coll Cardiol"},{"key":"2240_CR26","doi-asserted-by":"publisher","unstructured":"Lopes, R.D.; de Barros, E.S.P.G.M.; Furtado, R.H.M.; Macedo, A.V.S.; Bronhara, B.; Damiani, L.P.; Barbosa, L.M.; de Aveiro Morata, J.; Ramacciotti, E.; de Aquino Martins, P.; et al. Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial. Lancet 2021, 397, 2253\u20132263, doi:https:\/\/doi.org\/10.1016\/S0140-6736(21)01203-4.","DOI":"10.1016\/S0140-6736(21)01203-4"},{"key":"2240_CR27","doi-asserted-by":"publisher","unstructured":"Sholzberg, M.; Tang, G.H.; Rahhal, H.; AlHamzah, M.; Kreuziger, L.B.; Ainle, F.N.; Alomran, F.; Alayed, K.; Alsheef, M.; AlSumait, F.; et al. Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial. BMJ 2021, 375, n2400, doi:https:\/\/doi.org\/10.1136\/bmj.n2400.","DOI":"10.1136\/bmj.n2400"},{"key":"2240_CR28","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1001\/jamainternmed.2021.6203","volume":"181","author":"AC Spyropoulos","year":"2021","unstructured":"Spyropoulos AC, Goldin M, Giannis D, Diab W, Wang J, Khanijo S, Mignatti A, Gianos E, Cohen M, Sharifova G et al (2021) Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial. JAMA Intern Med 181:1612\u20131620. https:\/\/doi.org\/10.1001\/jamainternmed.2021.6203","journal-title":"JAMA Intern Med"},{"key":"2240_CR29","doi-asserted-by":"publisher","unstructured":"Ramacciotti, E.; Barile Agati, L.; Calderaro, D.; Aguiar, V.C.R.; Spyropoulos, A.C.; de Oliveira, C.C.C.; Lins Dos Santos, J.; Volpiani, G.G.; Sobreira, M.L.; Joviliano, E.E.; et al. Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): an open-label, multicentre, randomised, controlled trial. Lancet 2022, 399, 50\u201359, doi:https:\/\/doi.org\/10.1016\/S0140-6736(21)02392-8.","DOI":"10.1016\/S0140-6736(21)02392-8"},{"key":"2240_CR30","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1001\/jama.2021.17272","volume":"326","author":"JM Connors","year":"2021","unstructured":"Connors JM, Brooks MM, Sciurba FC, Krishnan JA, Bledsoe JR, Kindzelski A, Baucom AL, Kirwan BA, Eng H, Martin D et al (2021) Effect of Antithrombotic Therapy on Clinical Outcomes in Outpatients With Clinically Stable Symptomatic COVID-19: The ACTIV-4B Randomized Clinical Trial. JAMA 326:1703\u20131712. https:\/\/doi.org\/10.1001\/jama.2021.17272","journal-title":"JAMA"},{"key":"2240_CR31","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1001\/jama.2021.4152","volume":"325","author":"I Investigators","year":"2021","unstructured":"Investigators I, Sadeghipour P, Talasaz AH, Rashidi F, Sharif-Kashani B, Beigmohammadi MT, Farrokhpour M, Sezavar SH, Payandemehr P, Dabbagh A et al (2021) Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinical Trial. JAMA 325:1620\u20131630. https:\/\/doi.org\/10.1001\/jama.2021.4152","journal-title":"JAMA"}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-023-02240-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00392-023-02240-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-023-02240-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T08:05:20Z","timestamp":1697616320000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00392-023-02240-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,5]]},"references-count":31,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["2240"],"URL":"https:\/\/doi.org\/10.1007\/s00392-023-02240-1","relation":{},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"value":"1861-0684","type":"print"},{"value":"1861-0692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,5]]},"assertion":[{"value":"1 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors received a research grant from Bayer that was used together with the Funding of DZHK for conducting the study. S.D. Anker received grants and personal fees from Vifor and Abbott Vascular, and personal fees for consultancies, trial committee work and\/or lectures from Actimed, Amgen, Astra Zeneca, Bayer, Boehringer\u00a0Ingelheim, Bioventrix, Brahms, Cardiac Dimensions, Cardior, Cordio, CVRx, Cytokinetics, Edwards, Farraday Pharmaceuticals, GSK, HeartKinetics, Impulse Dynamics, Novartis, Occlutech,\u00a0Pfizer, Repairon, Sensible Medical, Servier, Vectorious, and V-Wave. Named co-inventor of two patent applications regarding MR-proANP (DE 102007010834 and DE 102007022367), but he does\u00a0not benefit personally from the related issued patents.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The clinical trial was approved according to local regulatory requirements by the lead ethical committee and was performed according to the Declaration of Helsinki. All participants were included in the study after giving written consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}}]}}